$5.22M Market Cap.
DRUG Market Cap. (MRY)
DRUG Shares Outstanding (MRY)
DRUG Assets (MRY)
Total Assets
$6.10M
Total Liabilities
$568.26K
Total Investments
$0
DRUG Income (MRY)
Revenue
$0
Net Income
-$2.80M
Operating Expense
$2.82M
DRUG Cash Flow (MRY)
CF Operations
-$1.85M
CF Investing
$0
CF Financing
$810.57K
DRUG Dividends (MRY)
Period | Dividends | Yield % | Growth % | Payout Ratio | Coverage Ratio |
|---|---|---|---|---|---|
2024 | $0 | 0% | 0% | 0% | - |
2023 | $0 | 0% | 0% | 0% | - |
2022 | $0 | 0% | 0% | 0% | - |
2021 | $0 | - | 0% | 0% | - |
2020 | $0 | - | - | 0% | - |
DRUG Balance Sheet (MRY)
Metric | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|
Total Assets | $6,104,602 (-11.26%) | $6,879,072 (-43.09%) | $12,086,984 (-39.69%) | $20,040,368 (2176.76%) |
Assets Current | $5,986,944 (-12.12%) | $6,812,659 (-42.98%) | $11,948,121 (-40.37%) | $20,038,368 (2181.71%) |
Assets Non-Current | $117,658 (77.16%) | $66,413 (-52.17%) | $138,863 (6843.15%) | $2,000 (0.00%) |
Goodwill & Intangible Assets | $0 (0%) | $0 (0%) | $0 (0%) | $2,000 (0.00%) |
Shareholders Equity | $5,536,343 (-16.09%) | $6,598,216 (-37.41%) | $10,542,512 (-45.66%) | $19,401,795 (2560.36%) |
Property Plant & Equipment Net | $117,658 (77.16%) | $66,413 (-52.17%) | $138,863 (0%) | $0 (0%) |
Cash & Equivalents | $5,720,092 (-15.23%) | $6,747,986 (-41.97%) | $11,627,913 (-41.15%) | $19,760,015 (2370.22%) |
Accumulated Other Comprehensive Income | $0 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
Deferred Revenue | $0 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
Total Investments | $0 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
Investments Current | $0 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
Investments Non-Current | $0 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
Inventory | $0 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
Trade & Non-Trade Receivables | $0 (0%) | $0 (0%) | $41,261 (0%) | $0 (0%) |
Trade & Non-Trade Payables | $449,299 (116.73%) | $207,307 (-85.24%) | $1,404,561 (119.95%) | $638,573 (323.11%) |
Accumulated Retained Earnings (Deficit) | -$34,348,969 (-8.88%) | -$31,547,023 (-30.50%) | -$24,174,798 (-162.49%) | -$9,209,857 (-1547.28%) |
Tax Assets | $50,224 (35.81%) | $36,981 (-67.71%) | $114,518 (3.97%) | $110,146 (0%) |
Tax Liabilities | $0 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
Total Debt | $39,576 (0%) | $0 (0%) | $71,983 (0%) | $0 (0%) |
Debt Current | $0 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
Debt Non-Current | $39,576 (0%) | $0 (0%) | $71,983 (0%) | $0 (0%) |
Total Liabilities | $568,259 (102.33%) | $280,856 (-81.82%) | $1,544,472 (141.86%) | $638,573 (323.11%) |
Liabilities Current | $528,683 (88.24%) | $280,856 (-80.93%) | $1,472,489 (130.59%) | $638,573 (323.11%) |
Liabilities Non-Current | $39,576 (0%) | $0 (0%) | $71,983 (0%) | $0 (0%) |
DRUG Income Statement (MRY)
Metric | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|
Revenues | $0 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
Cost of Revenue | $0 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
Selling General & Administrative Expense | $996,588 (-42.77%) | $1,741,401 (26.87%) | $1,372,629 (-0.99%) | $1,386,296 (6416.39%) |
Research & Development Expense | $1,180,010 (-76.40%) | $4,999,944 (-58.95%) | $12,180,938 (92.92%) | $6,313,988 (1679.33%) |
Operating Expenses | $2,822,767 (-61.78%) | $7,386,414 (-50.68%) | $14,975,092 (70.08%) | $8,804,862 (1732.91%) |
Interest Expense | $0 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
Income Tax Expense | $0 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
Net Loss Income from Discontinued Operations | $0 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
Consolidated Income | -$2,801,946 (61.99%) | -$7,372,225 (50.74%) | -$14,964,941 (-72.99%) | -$8,650,763 (-1700.83%) |
Net Income to Non-Controlling Interests | $0 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
Net Income | -$2,801,946 (61.99%) | -$7,372,225 (50.74%) | -$14,964,941 (-72.99%) | -$8,650,763 (-1700.83%) |
Preferred Dividends Income Statement Impact | $0 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
Net Income Common Stock | -$2,801,946 (61.99%) | -$7,372,225 (50.74%) | -$14,964,941 (-72.99%) | -$8,650,763 (-1700.83%) |
Weighted Average Shares | $4,310,168 (15.87%) | $3,719,775 (50.57%) | $2,470,383 (37.64%) | $1,794,805 (148.42%) |
Weighted Average Shares Diluted | $4,310,168 (15.87%) | $3,719,775 (50.57%) | $2,470,383 (37.64%) | $1,794,805 (148.42%) |
Earning Before Interest & Taxes (EBIT) | -$2,801,946 (61.99%) | -$7,372,225 (50.74%) | -$14,964,941 (-72.99%) | -$8,650,763 (-1700.83%) |
Gross Profit | $0 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
Operating Income | -$2,822,767 (61.78%) | -$7,386,414 (50.68%) | -$14,975,092 (-70.08%) | -$8,804,862 (-1732.91%) |
DRUG Cash Flow Statement (MRY)
Metric | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|
Net Cash Flow from Investing | $0 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
Net Cash Flow from Financing | $810,572 (-62.98%) | $2,189,686 (-57.86%) | $5,196,190 (-80.06%) | $26,055,600 (2484.03%) |
Net Cash Flow from Operations | -$1,850,186 (73.66%) | -$7,024,265 (48.30%) | -$13,587,116 (-85.63%) | -$7,319,301 (-2437.97%) |
Net Cash Flow / Change in Cash & Cash Equivalents | -$1,039,614 (78.50%) | -$4,834,579 (42.38%) | -$8,390,926 (-144.78%) | $18,736,299 (2502.49%) |
Net Cash Flow - Business Acquisitions and Disposals | $0 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
Net Cash Flow - Investment Acquisitions and Disposals | $0 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
Capital Expenditure | $0 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
Issuance (Repayment) of Debt Securities | -$89,730 (-4.20%) | -$86,112 (-1102.35%) | -$7,162 (0%) | $0 (0%) |
Issuance (Purchase) of Equity Shares | $900,000 (-26.08%) | $1,217,500 (-72.01%) | $4,350,161 (-84.33%) | $27,764,826 (2653.55%) |
Payment of Dividends & Other Cash Distributions | $0 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
Effect of Exchange Rate Changes on Cash | $11,720 (125.84%) | -$45,348 (-117.52%) | $258,824 (15.66%) | $223,787 (0%) |
Share Based Compensation | $839,771 (-27.11%) | $1,152,131 (31.66%) | $875,056 (-29.95%) | $1,249,165 (674.44%) |
Depreciation Amortization & Accretion | $73,357 (1.25%) | $72,450 (1100.10%) | $6,037 (0%) | $0 (0%) |
DRUG Financial Metrics (MRY)
Metric | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|
Gross Margin | - | - | - | - |
Profit Margin | - | - | - | - |
EBITDA Margin | - | - | - | - |
Return on Average Equity (ROAE) | -48.00% (44.25%) | -86.10% (35.75%) | -134.00% (-56.00%) | -85.90% (30.73%) |
Return on Average Assets (ROAA) | -43.40% (45.75%) | -80.00% (35.74%) | -124.50% (-50.54%) | -82.70% (17.13%) |
Return on Sales (ROS) | - | - | - | - |
Return on Invested Capital (ROIC) | 956.80% (-57.23%) | 2237.10% (-23.10%) | 2909.00% (-27.22%) | 3997.10% (354.89%) |
Dividend Yield | 0% (0%) | 0% (0%) | 0% | - |
Price to Earnings Ratio (P/E) | -2.45 (-124.38%) | -1.09 (18.70%) | -1.34 | - |
Price to Sales Ratio (P/S) | - | - | - | - |
Price to Book Ratio (P/B) | 1.28 (3.89%) | 1.24 (-32.44%) | 1.83 | - |
Debt to Equity Ratio (D/E) | 0.1 (139.53%) | 0.04 (-70.55%) | 0.15 (342.42%) | 0.03 (-84.06%) |
Earnings Per Share (EPS) | -0.65 (67.17%) | -1.98 (67.27%) | -6.05 (-26.04%) | -4.8 (-638.46%) |
Sales Per Share (SPS) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) |
Free Cash Flow Per Share (FCFPS) | -0.43 (77.28%) | -1.89 (65.67%) | -5.5 (-34.87%) | -4.08 (-922.06%) |
Book Value Per Share (BVPS) | 1.28 (-27.62%) | 1.77 (-58.43%) | 4.27 (-60.52%) | 10.81 (971.36%) |
Tangible Assets Book Value Per Share (TABVPS) | 1.42 (-23.42%) | 1.85 (-62.21%) | 4.89 (-56.18%) | 11.16 (818.17%) |
Enterprise Value Over EBIT (EV/EBIT) | 0 (0%) | 0 (0%) | -1 | - |
Enterprise Value Over EBITDA (EV/EBITDA) | -0.38 (-1923.81%) | 0.02 (103.01%) | -0.7 | - |
Asset Turnover | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) |
Current Ratio | 11.32 (-53.32%) | 24.26 (198.95%) | 8.11 (-74.14%) | 31.38 (439.27%) |
Dividends | $0 (0%) | $0 (0%) | $0 (0%) | $0 (0%) |
Free Cash Flow (FCF) | -$1,850,186 (73.66%) | -$7,024,265 (48.30%) | -$13,587,116 (-85.63%) | -$7,319,301 (-2437.97%) |
Enterprise Value (EV) | $769,276 (777.14%) | -$113,607 (-101.44%) | $7,904,099 | - |
Earnings Before Tax (EBT) | -$2,801,946 (61.99%) | -$7,372,225 (50.74%) | -$14,964,941 (-72.99%) | -$8,650,763 (-1700.83%) |
Earnings Before Interest Taxes & Depreciation Amortization (EBITDA) | -$2,728,589 (62.62%) | -$7,299,775 (51.20%) | -$14,958,904 (-72.92%) | -$8,650,763 (-1700.83%) |
Invested Capital | -$104,597 (30.16%) | -$149,770 (84.09%) | -$941,435 (-161.35%) | -$360,220 (-395.92%) |
Working Capital | $5,458,261 (-16.44%) | $6,531,803 (-37.65%) | $10,475,632 (-46.00%) | $19,399,795 (2567.40%) |
Tangible Asset Value | $6,104,602 (-11.26%) | $6,879,072 (-43.09%) | $12,086,984 (-39.68%) | $20,038,368 (2181.71%) |
Market Capitalization | $5,222,689 (-13.46%) | $6,035,315 (-58.67%) | $14,602,389 | - |
Average Equity | $5,838,471 (-31.79%) | $8,559,360 (-23.34%) | $11,164,894 (10.92%) | $10,065,544 (2498.98%) |
Average Assets | $6,450,179 (-30.03%) | $9,219,072 (-23.31%) | $12,020,620 (14.92%) | $10,460,292 (2074.23%) |
Invested Capital Average | -$292,846 (11.14%) | -$329,544 (35.94%) | -$514,435 (-137.69%) | -$216,428 (-295.87%) |
Shares | 4,463,837 (18.34%) | 3,772,072 (58.87%) | 2,374,372 (0.32%) | 2,366,872 (20.47%) |
